News and Announcements
Blockchain startup Havven raises $39 million in Australia’s largest ICO
- Published December 20, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Havven raised $39 million in ICO.
- The token sale was over in 90 minutes.
- Public contributors to the sale were left with approximately 1.2 million of the startup’s HAV tokens (or around $US4 million worth of tokens), to get their hands on.
Blockchain startup Havven finalised a $US30 million ($38.6 million) initial coin offering (ICO) this year.
Kicking off at 7.00am, the token sale was over in just 90 minutes. But the full $US30 million was not sold in that time, as the company had already completed a massive $US26 million pre-sale from high net worth individuals and crypto investment funds.
Public contributors to the sale were left with approximately 1.2 million of the startup’s HAV tokens (or around $US4 million worth of tokens), to get their hands on.
To read the full article, click here.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
